RJA
ADMA icon

Raymond James & Associates’s ADMA Biologics ADMA Stock Holding History

Raymond James & Associates’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-15,000
Closed -$1K – 4083
2021
Q1 		$1K Sell
15,000
-3,000
-17% -$6.87K ﹤0.01% 3982
2020
Q4 		$1K Buy
18,000
+1,000
+6% +$2.1K ﹤0.01% 3746
2020
Q3 		$1K Buy
+17,000
New +$46.6K ﹤0.01% 3572

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Raymond James & Associates's ADMA Position: Q3 2024 in Review

Raymond James & Associates reduced its ADMA Biologics (ADMA) stake by 5% in Q3 2024, selling an estimated $215K and leaving 264,392 shares worth $5.29M. The position accounts for ﹤0.01% of the portfolio, ranked #1621.

Raymond James & Associates first reported a position in ADMA in Q2 2016 and has held it in 27 quarters since. 306 funds tracked by Wall St. Rank hold ADMA as of Q3 2024.

  • Raymond James & Associates held 264,392 shares of ADMA Biologics worth $5.29M as of Q3 2024.
  • Raymond James & Associates sold 13,835 ADMA Biologics shares in Q3 2024, an estimated $215K.
  • ADMA Biologics made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #1621 holding.
  • Raymond James & Associates first reported a position in ADMA Biologics in Q2 2016 and has held it in 27 quarters since.
  • 306 funds tracked by Wall St. Rank held ADMA Biologics as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.